 |
|
|
| |
Long-term Follow-Up of Patients With Chronic HCV and No or Minimal Fibrosis Shows Low Risk for Liver-Related Morbidity and Mortality After Achieving SVR With DAA-Based Therapy: Results From the Gilead SVR Registry
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting 2017, October 20-24, 2017, Washington, DC
Marc Bourlière,1 Ed Gane,2 Ira M. Jacobson,3 Stuart C. Gordon,4 Mark Sulkowski,5 Brian McNabb,6 Frances Chen,6 Hadas Dvory-Sobol,6 John McNally,6 Diana M. Brainard,6 G. Mani Subramanian,6 Alnoor Ramji,7 Stefan Zeuzem,8 Kosh Agarwal,9 K. Rajender Reddy10
1Hôpital Saint Joseph Marseille, France; 2New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 3Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, NY; 4Henry Ford Health System, Detroit, MI; 5The Johns Hopkins University School of Medicine, Baltimore, MD; 6Gilead Sciences, Inc., Foster City, CA; 7The University of British Columbia, Vancouver, Canada; 8Goethe-Universität Frankfurt am Main, Germany; 9King's College Hospital, London, UK; 10University of Pennsylvania, Philadelphia
Reference
1. Xu F, et al. Clin Infect Dis 2016;62:289-97.
|
| |
|
|
|
|
|
